Skip to Content

Clinical Trials

Untreated Mantle Cell Lymphoma

2013-0056: A Randomized, Double-blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects with Newly Diagnosed Mantle Cell Lymphoma.

2006-0697: Bortezomib + R-HyperCVAD alternating with Bortezomib +  R-High dose Methotrexate/Cytarabine in Untreated Aggressive Mantle Cell Lymphoma.

Previously Treated Mantle Cell Lymphoma

2013-0090: A Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma.

2012-0696: An Open-Label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma.

2012-0750: A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma.

2012-1107: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.

2013-0435: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma. 


© 2014 The University of Texas MD Anderson Cancer Center